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Background: Androgen receptor (AR) plays an important role in the pathogenesis of prostate cancer and
acne. Dimethoxycurcumin is a newly found enhancer of AR degradation, which highlights its potential
for treatment of AR-related disorders. Follicular hyperkeratosis is one essential factor in the complicated
pathogenesis of acne, in which some dermatopathologists have observed overexpressed psoriasin, an
activator protein (AP)-1-targeted gene product.
Methods: We used the HaCaT cell line to determine the effect of dimethoxycurcumin on expression of
AP-1 subunits and AP-1-targeted genes, psoriasin and cyclin D1, by luciferase reporter assay, western
blotting and reverse transcriptase polymerase chain reaction. We also used ﬂow cytometry to analyze
changes in cell populations in response to increasing dose of dimethoxycurcumin.
Results: Dimethoxycurcumin inhibits psoriasin promoter activities at the basal or enhanced level induced
by exogenous c-Jun/c-Fos heterodimeric AP-1. Expression of endogenous c-Jun and c-Fos, two important
subunits of dimeric AP-1, was downregulated at the mRNA or protein level by dimethoxycurcumin in
HaCaT cells. Inhibition of endogenous cyclin D1 occurred at both the transcript and protein levels. A shift
of subpopulations of cells into sub-G1 phase was consistent with reduced cyclin D1, corresponding to
dimethoxycurcumin treatment.
Conclusion: Identiﬁcation of AP-1 transcription factor as a speciﬁc target for dimethoxycurcumin-
downregulated molecules in human keratinocytes suggests that this novel chemical modulates various
AP-1erelated events in the epidermis, including cell-cycle progression and its role as an inﬂammatory
reservoir. We provided evidence for this because expression of cyclin D1 and psoriasin, two AP-1-
regulated gene products, was inhibited by dimethoxycurcumin in HaCaT and HeLa cells. Cyclin D1 is
an important cell-cycle regulator, whereas psoriasin is a potent cytokine for innate immunity. We
anticipate that more diseases will beneﬁt from this curcumin analog in the near future.
Copyright  2011, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Acne vulgaris is an inﬂammatory skin disorder that affects many
people worldwide. Besides the physical discomfort, the cosmetic
sequelae can have a major psychosocial impact on the patient’s
life.1 In some cases, acne also lowers self-esteem, whichmay lead to
signiﬁcant depressive mood.2 A large body of evidence also indi-
cates that acne may impair the patients’ daily quality of life, toSection 2, Chenggong Road,
6 2 8792 7180; fax: þ886 2
Wang).
iwanese Dermatological Associatiowhich physicians need to pay more attention to achieve a satisfac-
tory therapeutic goal.3,4
Pathogenesis is signiﬁcantly related to androgen production, or
more exactly, androgen sensitivity.5e7 This implies that androgens
and their receptors play important roles in acne formation. Acne is
known to result from a recalcitrant inﬂammatory process caused by
Propionibacterium acne infection in the blocked follicles on the
affected skin. The blockage results from follicular hyperkeratosis
located at the oriﬁce, which causes the retention of overproduced
sebum and leads to P. acne overgrowth. The bacterial overgrowth
induces innate antibacterial peptides such as psoriasin, which is
a strong neutrophil attractant and it also enhances the hyper-
proliferation of epidermal keratinocytes.8e12 We can easily tell that
there is a vicious cycle for the inﬂammatory acne to progress.n. Published by Elsevier Taiwan LLC. All rights reserved.
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led to variable outcomes in individual patients.13 In general, these
therapeutic agents do not cover all the above-mentioned aspects, but
alone they can interrupt the vicious inﬂammatory cycle, or in
combination, they can cover most aspects of the ongoing inﬂam-
mation. For example, topical agents that contain benzoyl peroxide at
a concentration of 5e10% can inhibit P. acne overgrowth within
lesions. Benzoyl peroxide also exhibits signiﬁcant anti-inﬂammatory
and keratolytic activities.14 Tetracyclines can also inhibit P. acne due
to its antibiotic property, but it is also known that tetracyclines
exhibit an anti-inﬂammatory effect through some mechanisms that
await further exploration.15e17 Retinoids have been used to treat acne
because they can inhibit follicular hyperkeratosis and sebum
production, although they exert no signiﬁcant effect on the antibac-
terial or anti-inﬂammatory aspects.18
A novel agent, dimethoxycurcumin, a curcumin analog, has
potential for treatment of prostate cancer and spinal and bulbar
muscular atrophy.19e21 It is known that part of the reason for
recurrence of prostate cancer is the intrinsic escape mechanism
developed in the cancer cells.22,23 For example, prostate cancer cells
may acquire a ligand-independent way to waive the necessity of
hormones for cell growth. Intracellular overexpressed ARs have
been found to play a role in recalcitrant prostate cancer. The newly
found dimethoxycurcumin is a highly selective inhibitor that works
through a pathway to induce degradation of AR, thereby leading to
apoptosis of the prostate cancer cells.21 It seems promising but
awaits further clinical trials. Likewise, it may also be used to treat
acne because androgens play an important role in the pathogenesis
of acne. Dimethoxycurcumin has been used in an early clinical trial
to test its application for acne treatment (available at: http://
clinicaltrials.gov/ct2/show/NCT00525499).
Additionally, it has been reported previously that androgen
deprivation downregulates S100P expression in LNCaP prostate
cancer cells.24 Interestingly, many of the members of the S100
protein family, including S100P and psoriasin (also known as
S100A7), can be detectable in normal or diseased epidermis.10,25 As
wementioned earlier, psoriasin is upregulated in acne lesions.8,9 AR
is a well-known ubiquitous transcription factor whose target genes
regulate many cellular functions including survival, proliferation
and differentiation, therefore, we established experiments to
explore whether dimethoxycurcumin affects the expression of
psoriasin, which plays a dual role in inﬂammation and epidermal
hyperplasia. Importantly, our work disclosed that, beyond ARs,
activator protein (AP)-1 is another transcription factor that is
inhibited by dimethoxycurcumin.
Methods
Plasmids
Reporter gene psoriasin (e743/þ1)-LUC was constructed by the
polymerase chain reaction (PCR) product cut with KpnI/XhoI and
sub-cloned into the KpnI and XhoI sites of the pGL3-SV40-LUC
vector. Various AP-1 proteins fused with the pCI vector were
a gift from D Chalbos (Institute National de la Santé et de la
Recherche Médicale, France), served as PCR templates for various
AP-1-coding regions and were then sub-cloned into the EcoRI and
XhoI sites of the pSG5.HA vector, which has promoters for in vitro
and mammalian cell expression with an N-terminal HA-tag.26
Cell culture, reagents and transient transfection assays
For functional assays, HeLa and HaCaT cells were grown in Dul-
becco’s Modiﬁed Eagle’s Medium (DMEM) supplemented with 10%charcoal/dextran-treated fetal bovine serum (Life Technologies,
Carlsbad, CA, USA). Transient transfection (jetPEI, PolyPlus-
transfection) luciferase assays (Promega, Madison, WI, USA) were
performed in 24-well culture dishes as described previously.27,28
Total DNA was adjusted to 1 mg by adding the necessary amount
of the respective empty vector. The transfected cell extract lucif-
erase activity is presented in relative light units and expressed as
the mean and standard deviation from three transfected cultures.
Dimethoxycurcumin was purchased from the Cayman Chemical
Company, Ann Arbor, MI, USA.
Cell viability assay
Cells were seeded in 96-well culture plates and were allowed to
grow for 1 day. The cells were then exposed to the indicated
concentration of dimethoxycurcumin in fresh DMEM for 24 hours.
3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) solution (0.5 mg/mL in phosphate-buffered saline; PBS) was
added to each well and the plate was incubated for 2 hours at
37 C. Dimethylsulfoxide (DMSO) (E.Merck, Darmstadt, West
Germany, 150 ml) was then added as a solubilizing agent and the
absorbance at 540 nm was measured using an ELISA plate reader
(Multiskan EX, Thermo, USA). As a control, cells treated with
medium containing no dimethoxycurcumin were set as 100% cell
survival.
Immunoblotting
The cell extracts were lysed in RIPA buffer (100 mM TriseHCl, pH
8.0, 150 mMNaCl, 0.1% SDS, and 1% Triton 100) at 4 C, separated by
SDS-PAGE and analyzed via immunoblotting, with antibodies
against c-Fos, cyclin D1 and actinin (ACTN) (Santa Cruz, Biotech-
nology, Santa Cruz, CA, USA).
Reverse transcriptase PCR
Total RNA was extracted from growing cells using a total RNA
reagent kit (Bioman, Taiwan) according to the manufacturer’s
instructions. One microgram of total RNA was subjected to reverse
transcription using Moloney Murine Leukemia Virus reverse tran-
scriptase for 1 hour at 37 C (Epicentre Biotechnologies, Madison,
WI, USA). PCR was performed in the linear range (30 cycles) with
primers speciﬁc for cyclin D1, c-Fos, c-jun andGAPDH. The sequences
of the primers for the ampliﬁcation of target genes were as follows:
cyclin D1 top-strand, 50-ATGGAACACCAGCTCCTGTGCTGC-30; cyclin
D1 bottom-strand, 50-TCAGATGTCCACGTCCCGCACGTCGG-30; c-Fos
top-strand, 50-GACTACGAGGCGTCATCCTC-30; c-Fos bottom-strand,
50-GCTCTGGTCTGCGATGGGGCC-30; c-Jun top-strand, 50-ATGACTG
CAAAGATGGAAACGACC-30; c-Jun bottom-strand, 50-TCGGCGAA
GCCCTCCTGCTC-30; GAPDH top-strand, 50-AACGGATTTGGCCGTAT
TGGG-30; GAPDH bottom-strand, 50-GGGATGACCTTGCCCACAG
CC-30. The thermocycling conditions were as follows: one cycle at
95 C for 5 minutes followed by 30 cycles of 95 C for 45 seconds,
55 C for 30 seconds, and 72 C for 40 seconds. Ampliﬁed products
were subjected to 1.2% agarose gel electrophoresis and visualized by
staining with ethidium bromide.
Fluorescence-activated cell sorting
This analysis was based on the measurement of DNA content of
nuclei labeled with propidium iodide. For cell cycle evaluation,
cells were treated as for the proliferation experiments, washed
with ice-cold PBS and incubated with propidium iodide (0.05%
mg/mL in PBS, 0.1% Triton X-100, and 0.01% RNase) for 15 minutes
Figure 2 Effects of dimethoxycurcumin on psoriasin promoter activity in HaCaT and
HeLa cells. HaCaT (A) and HeLa (B) cells were co-transfected with 0.25 mg
psoriasin(e743/þ1)-LUC and, where indicated, 0.25 mg empty vector or c-Jun/c-Fos
complex. The transfected cells were treated with vehicle (closed) or 5 mM dimethox-
ycurcumin (open) for 36 hours. (C) HaCaT cells were transfected with 0.25 mg
psoriasin(e743/þ1)-LUC and treated with indicated amount of dimethoxycurcumin for
36 hours. Luciferase activities in the transfected cell extracts were then determined
The numbers above the columns indicate the luciferase activity relative to an index of 1
for samples to which neither AP-1 nor dimethoxycurcumin was added. These data are
the average of three independent experiments (mean  standard deviation; n ¼ 3).
RLU ¼ relative light units.
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ﬂuorescence-activated cell sorting, and analysis of the cell cycle
was evaluated using FACSCalibur ﬂow cytometry (Bectone
Dickinson Biosciences, Franklin Lakes, NJ, USA). Datawere analyzed
using the Cell Quest Pro software package (BectoneDickinson
Biosciences).
Statistical analysis
Comparisons between groups were determined by a two-tailed
t test (SPSS Advanced Statistics 17.0). A p value <0.05 was re-
ported as a signiﬁcant difference between groups.
Results
Dimethoxycurcumin decreases viability of HaCaT cells
We measured the viability of HaCaT cells in the presence of dime-
thoxycurcumin using the MTT assay. The IC50 for HaCaT cells
incubated for 24 hours was around 18 mM (Figure 1), which is
higher than that against prostate cancer cell lines.21
Dimethoxycurcumin inhibits AP-1 transcriptional activity and
psoriasin-promoter activity
Psoriasin has been shown to be overexpressed in the keratinocytes
of acne lesions.8,9 It has been reported that there is an AP-1 binding
site in the psoriasin promoter, therefore, we established experi-
ments to evaluate psoriasin promoter activity using luciferase
reporter assay, with or without transfection of exogenous c-Jun and
c-Fos, to reconstitute the prototypic heterodimeric AP-1 tran-
scription factor. Overexpressed c-Jun/c-Fos indeed activates the
psoriasin promoter (Figure 2A, comparing column 2 to column 1,
closed bar; p ¼ 0.003). Interestingly, in the presence of dimethox-
ycurcumin, the AP-1-activated promoter activity was reduced,
indicating dimethoxycurcumin negatively regulates the transcrip-
tional activity of AP-1 (Figure 2A, column 2, comparing closed bar
to open bar). In support, reduced basal promoter activity indicated
that the endogenous transcriptional activators for psoriasin
promoter were also inhibited by dimethoxycurcumin (Figure 2A,
column 1, comparing closed bar to open bar). This prompted us to
start a detailed investigation of the effect of dimethoxycurcumin
treatment on the endogenous AP-1 in human keratinocytes.Figure 1 IC50 of dimethoxycurcumin in HaCaT cells. HaCaT cells were treated with
indicated amount of dimethoxycurcumin for 24 hours. MTT assays were per-
formed at the indicated times. Results are representative of two independent
experiments.Moreover, similar results were observed using HeLa cells
(Figure 2B), suggesting that inhibition of AP-1 by dimethox-
ycurcumin might be a general instead of a cell-speciﬁc event. The
concentration of dimethoxycurcumin to reduce 50% of psoriasin
promoter activity in HaCaT cells was measured at 5 mM (Figure 2C),
which is the concentration that we chose to perform the luciferase
activity assays (Figure 2A and 2B).Figure 3 Effects of dimethoxycurcumin on protein expression of cyclin D1 and c-Fos in
HaCaT and HeLa cells. HaCaT and HeLa cells were treated with indicated amount of
dimethoxycurcumin for 24 hours. Cells were subject to immunoblotting for detection
of cyclin D1, c-Fos and ACTN (loading control). The data shown here are the repre-
sentative of three independent experiments.
Figure 5 Cell cycle proﬁles of HaCaT cells treated with dimethoxycurcumin. HaCaT
cells were treated with indicated amount of dimethoxycurcumin for 36 hours. Fixed
cells were stained with propidium iodide, and DNA content was determined by
ﬂuorescence-activated cell sorting analysis. The results are representatives of three
independent experiments.
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Using western blotting, we checked the amount of endogenous
c-Fos protein, one subunit of AP-1, and cyclin D1, which is also an
AP-1-targeted gene product.29 As anticipated, the expression of
cyclin D1 was inhibited by dimethoxycurcumin in a dose-
dependent manner (Figure 3, lanes 1e5, upper panel). Interest-
ingly, the expression of c-Fos showed a similar pattern, indicating
that endogenous AP-1 may be a downregulating target for dime-
thoxycurcumin (Figure 3, lanes 1e5, middle panel). Again, a similar
theme was also observed in HeLa cells (Figure 3, lanes 6e10).
Dimethoxycurcumin inhibits transcription of c-Jun but not
c-Fos genes
Using RT-PCR, we determined whether the inhibition of endoge-
nous AP-1 took place at the transcription level. Figure 4 shows that,
in the presence of 15 mMdimethoxycurcumin, transcription of c-Jun
decreased in a time-dependent manner (lanes 1e6, uppermost
panel). However, a similar effect was not observed for c-Fos tran-
scription (upper second panel). In contrast, the transcription of
cyclin D1 was apparently inhibited. The downregulated transcrip-
tion of cyclin D1 gene supports the inhibitory effect of dimethox-
ycurcumin on the transcriptional activity of AP-1 (Figure 1),
although other factors in addition to AP-1 may also be affected by
dimethoxycurcumin (see Discussion).
Sub-G1 population of HaCaT cells increased with treatment
with dimethoxycurcumin in a dose-dependent manner
Cyclin D1 promoted G1/S transition in the cell cycle. The amount of
cyclin D1 was decreased by dimethoxycurcumin, therefore, we
used ﬂow cytometry to observe the distribution of the cell pop-
ulation as a function of cyclin D1 in the presence of increasing
concentrations of dimethoxycurcumin. The HaCaT cell populationFigure 4 Effects of dimethoxycurcumin on transcription of c-Jun, c-Fos and cyclin D1
in HaCaT cells. HaCaT cells were treated with 15 mM dimethoxycurcumin for indi-
cated time where mRNA was collected and then assessed by RT-PCR. The data shown
here are representative of three independent experiments. The intensity of each band
was quantitated and expressed as percentage relative to the intensity of respective
glyceraldehyde 3 phosphate dehydrogenase transcript (internal control) collected
at the same indicated timepoints. RT-PCR ¼ reverse transcriptase polymerase chain
reaction.apparently shifted towards the subG1 phase, particularly as
concentration increased towards the IC50 (Figure 5).
Discussion
We demonstrated that dimethoxycurcumin inhibited psoriasin
promoter activity at both basal and AP-1-activated levels. What is
important for us is that psoriasin is one of the innate antimicrobial
peptides that are secreted by keratinocytes.25 The review of
Watson et al has shown that psoriasin may attract inﬂammatory
cells to inﬂammatory skin lesions and cause epidermal hyper-
plasia.10 The prevention of keratinocytes from production of
psoriasin by treatment with dimethoxycurcumin would be bene-
ﬁcial for acne control because follicular hyperkeratosis and local
inﬂammation would be alleviated. This awaits pathological
veriﬁcation when the topical medication is available for further
clinical investigation.
Interestingly, psoriasin promoter has been shown to harbor an
AP-1-binding site, which is a positive regulatory cis-acting element
deﬁned in the keratinocyte cell line KHSV40.30 We used human
keratinocyte cell line HaCaT to demonstrate that the luciferase
reporter activity driven by psoriasin promoter can be activated by
the AP-1 transcription factor, whose prototype is c-Jun/c-Fos het-
erodimer, as shown in several previous studies.31e34 AP-1, similar to
AR, is also ubiquitously present in different types of cells, and it is
actively engaged in many aspects of skin physiology, including
epidermal homeostasis and carcinogenesis.32,35e39 Moreover, our
data indicate that not only AR, but also AP-1, is the target for
dimethoxycurcumin to carry out its pharmacologic effects, such as
induction of apoptosis (Figure 1 and ref. 21). The amount of AP-1
complex in human keratinocytes may be reduced by dimethox-
ycurcumin because the expression level of both endogenous c-Jun
and c-Fos is repressed. In support, we observed a reduced protein
level of cyclin D1, which is an AP-1-responsive gene product
(Figure 2). However, the molecular mechanisms are not the same
for the regulation of c-Jun and c-Fos expression. Inhibition of c-Jun
expression level occurs at the transcriptional level because we
observed that the amount of mRNA transcript was reduced, as
shown by RT-PCR. For c-Fos, the amount of protein but not tran-
script was decreased after dimethoxycurcumin treatment. We
speculate that the inhibition of c-Fos expression by dimethox-
ycurcumin may occur at the post-transcriptional or even post-
translational level. It would be interesting to investigate further
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enhanced by dimethoxycurcumin; similar to the lessons learned
from AR.21,40
As we know, cyclin D1 is one of the important regulators for the
transition from G1 to S phase in the cell cycle.41,42 We observed
reduced cyclin D1 expression at both the transcript and protein
levels. The inhibitionof cyclinD1expressionbydimethoxycurcumin
indicates that this novel agent might inhibit the proliferation of
human keratinocytes through interference with the cell cycle.
Moreover, the dimethoxycurcumin-induced reduction in cyclin D1
and c-Fos has also been observed in HeLa cells, in which sex
hormones and AP-1 also affect gene expression signiﬁcantly.43,44
Our data imply that dimethoxycurcumin may also have a potential
role in interfering with the pathogenesis of cervical cancer. In
addition, the protein level of cyclin D1 began to decrease at lower
concentrations of dimethoxycurcumin compared with that for
c-Fos, as shown by western blotting in HaCaT cells (Figure 3). This
might have resulted from inhibition of some other activators such as
ternary complex factor or nuclear factor-kB, whose binding sites are
highly conserved across species and crucial for regulation of cyclin
D1 expression. These unexplored factorsmight also be the potential
targets for dimethoxycurcumin.45 Moreover, formation of the
derepression complex containing c-Jun/c-Fos/estrogen receptor,
which is able to displace the repressor complex containing Ying-
Yang 1 and histone deacetylase 1 might also be disrupted because
the amount of Jun/Fos subunits may be decreased by dimethox-
ycurcumin treatment.46
In summary, dimethoxycurcumin might inhibit the follicular
hyperkeratosis shown in acne lesions by downregulating two
factors, psoriasin and cyclin D1. Dimethoxycurcumin might be
of beneﬁt for acne control, and interfere with carcinogenesis of
various cell types. Moreover, our data expand the repertoire of
transcriptomes that are affected by dimethoxycurcumin, including
those related to AR and AP-1, and other transcription factors await
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